Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Human Neurons Derived From Induced Pluripotent Stem Cells as a New Platform for Preclinical Drug Screening and Development

Human Neurons Derived From Induced Pluripotent Stem Cells as a New Platform for Preclinical Drug... Opinion EDITORIAL Human Neurons Derived From Induced Pluripotent Stem Cells as a New Platform for Preclinical Drug Screening and Development Fan Liao, PhD; David M. Holtzman, MD Alzheimer disease (AD) is the most common dementia, with an carried out by Eli Lilly was terminated before completion ow- estimated prevalence of 30 million people worldwide. Cur- ing to an overall worsening of cognition and an increase in ad- rently, there is no effective treatment that delays the onset or verse effects including skin cancers and infections in those slows the progression of AD. treatedwiththe GSI. The adverse effects were thought to oc- β-Amyloid (Aβ), the key com- cur because Notch signaling or other non-APP γ-secretase tar- Related article page 1481 ponent of plaques, is thought gets was altered by semagacestat. However, although the to play a pivotal role in the initiation of AD pathogenesis. Pre- plasma Aβ was reduced by semagacestat, the cerebrospinal viously, all clinical trials of Aβ-targeted therapeutics have failed. fluid Aβ at the time selected for assessment was unaltered. There are several possible reasons for this, one of which is that In the article by Liu et al, neurons derived from human the preclinical drug discovery and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Neurology American Medical Association

Human Neurons Derived From Induced Pluripotent Stem Cells as a New Platform for Preclinical Drug Screening and Development

Liao, Fan; Holtzman, David M.
JAMA Neurology , Volume 71 (12) – Dec 1, 2014
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/human-neurons-derived-from-induced-pluripotent-stem-cells-as-a-new-Rc21oHEuwL

References (12)

Publisher
American Medical Association
Copyright
Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6149
eISSN
2168-6157
DOI
10.1001/jamaneurol.2014.2802
pmid
25285675
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL Human Neurons Derived From Induced Pluripotent Stem Cells as a New Platform for Preclinical Drug Screening and Development Fan Liao, PhD; David M. Holtzman, MD Alzheimer disease (AD) is the most common dementia, with an carried out by Eli Lilly was terminated before completion ow- estimated prevalence of 30 million people worldwide. Cur- ing to an overall worsening of cognition and an increase in ad- rently, there is no effective treatment that delays the onset or verse effects including skin cancers and infections in those slows the progression of AD. treatedwiththe GSI. The adverse effects were thought to oc- β-Amyloid (Aβ), the key com- cur because Notch signaling or other non-APP γ-secretase tar- Related article page 1481 ponent of plaques, is thought gets was altered by semagacestat. However, although the to play a pivotal role in the initiation of AD pathogenesis. Pre- plasma Aβ was reduced by semagacestat, the cerebrospinal viously, all clinical trials of Aβ-targeted therapeutics have failed. fluid Aβ at the time selected for assessment was unaltered. There are several possible reasons for this, one of which is that In the article by Liu et al, neurons derived from human the preclinical drug discovery and

Journal

JAMA Neurology – American Medical Association

Published: Dec 1, 2014

There are no references for this article.